These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 3120274)

  • 1. Use of Pseudomonas aeruginosa toxin A in the construction of conjugate vaccines and immunotoxins.
    Cryz SJ; Fürer E; Sadoff JC; Germanier R; Pastan I; Willingham MC; FitzGerald DJ
    Rev Infect Dis; 1987; 9 Suppl 5():S644-9. PubMed ID: 3120274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
    Cryz SJ; Fürer E; Sadoff JC; Germanier R
    Antibiot Chemother (1971); 1987; 39():249-55. PubMed ID: 3118786
    [No Abstract]   [Full Text] [Related]  

  • 3. Vaccine potential of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugates.
    Cryz SJ; Lang AB; Sadoff JC; Germanier R; Fürer E
    Infect Immun; 1987 Jul; 55(7):1547-51. PubMed ID: 3110065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and characterization of Escherichia coli O18 O-polysaccharide conjugate vaccines.
    Cryz SJ; Cross AS; Sadoff JC; Fürer E
    Infect Immun; 1990 Feb; 58(2):373-7. PubMed ID: 2105272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine.
    Cryz SJ; Fürer E; Que JU
    Infect Immun; 1991 Jan; 59(1):45-50. PubMed ID: 1898901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine.
    Cryz SJ; Furer E; Sadoff JC; Germanier R
    Infect Immun; 1986 Apr; 52(1):161-5. PubMed ID: 3082756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of Escherichia coli O18 O-specific polysaccharide (O-PS)-toxin A and O-PS-cholera toxin conjugate vaccines in humans.
    Cryz SJ; Cross AS; Sadoff JC; Wegmann A; Que JU; Fürer E
    J Infect Dis; 1991 May; 163(5):1040-5. PubMed ID: 1708398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and characterization of a polyvalent Escherichia coli O-polysaccharide-toxin A conjugate vaccine.
    Cryz SJ; Que JO; Cross AS; Fürer E
    Vaccine; 1995 Apr; 13(5):449-53. PubMed ID: 7639013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is Pseudomonas aeruginosa exotoxin A a good carrier protein for conjugate vaccines?
    Pier GB
    Hum Vaccin; 2007; 3(2):39-40; author reply 41. PubMed ID: 17268204
    [No Abstract]   [Full Text] [Related]  

  • 10. [Protective polysaccharide-protein artificial antigens from O-specific polysaccharides of Pseudomonas aeruginosa and its exotoxin A].
    Dmitriev BA; Kul'shin VA; Antsiferova NG; Vovk VA; Moroz AF
    Dokl Akad Nauk SSSR; 1988; 298(5):1277-80. PubMed ID: 2454182
    [No Abstract]   [Full Text] [Related]  

  • 11. The novel multispecies Fc-specific Pseudomonas exotoxin A fusion protein α-Fc-ETA' enables screening of antibodies for immunotoxin development.
    Klausz K; Kellner C; Derer S; Valerius T; Staudinger M; Burger R; Gramatzki M; Peipp M
    J Immunol Methods; 2015 Mar; 418():75-83. PubMed ID: 25701195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A.
    Fattom A; Schneerson R; Szu SC; Vann WF; Shiloach J; Karakawa WW; Robbins JB
    Infect Immun; 1990 Jul; 58(7):2367-74. PubMed ID: 2114365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.
    Cryz SJ; Fürer E; Cross AS; Wegmann A; Germanier R; Sadoff JC
    J Clin Invest; 1987 Jul; 80(1):51-6. PubMed ID: 3110215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clearance of Pseudomonas aeruginosa from normal rat lungs after immunization with somatic antigens or toxin A.
    Johansen HK; Cryz SJ; Høiby N
    APMIS; 1994 Jul; 102(7):545-53. PubMed ID: 7917224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation, characterization, and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccines.
    Konadu E; Robbins JB; Shiloach J; Bryla DA; Szu SC
    Infect Immun; 1994 Nov; 62(11):5048-54. PubMed ID: 7927787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monovalent immunotoxin containing truncated form of Pseudomonas exotoxin as potent antitumor agent.
    Debinski W; Pastan I
    Cancer Res; 1992 Oct; 52(19):5379-85. PubMed ID: 1394141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A.
    Fattom A; Schneerson R; Watson DC; Karakawa WW; Fitzgerald D; Pastan I; Li X; Shiloach J; Bryla DA; Robbins JB
    Infect Immun; 1993 Mar; 61(3):1023-32. PubMed ID: 8432585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of tetanus toxoid conjugates of anti-idiotypes that mimic Pseudomonas aeruginosa surface polysaccharides.
    Schreiber JR; Dahlhauser P
    Infect Immun; 1994 Jan; 62(1):308-12. PubMed ID: 8262644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of immunotoxins using Pseudomonas exotoxin A.
    FitzGerald DJ
    Methods Enzymol; 1987; 151():139-45. PubMed ID: 3123880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
    Cryz SJ; Lang A; Rüdeberg A; Wedgwood J; Que JU; Fürer E; Schaad U
    Behring Inst Mitt; 1997 Feb; (98):345-9. PubMed ID: 9382759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.